- Home
- GAME vs GNTA Comparison
GAME vs GNTA Comparison
Compare GAME & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- GNTA
- Stock Information
- Founded
- GAME 2011
- GNTA 2014
- Country
- GAME United States
- GNTA Italy
- Employees
- GAME N/A
- GNTA N/A
- Industry
- GAME
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GAME
- GNTA Health Care
- Exchange
- GAME Nasdaq
- GNTA Nasdaq
- Market Cap
- GAME 68.2M
- GNTA 59.7M
- IPO Year
- GAME 2009
- GNTA 2021
- Fundamental
- Price
- GAME $0.69
- GNTA $2.40
- Analyst Decision
- GAME Strong Buy
- GNTA
- Analyst Count
- GAME 2
- GNTA 0
- Target Price
- GAME $3.00
- GNTA N/A
- AVG Volume (30 Days)
- GAME 2.2M
- GNTA 1.2M
- Earning Date
- GAME 11-13-2025
- GNTA 01-01-0001
- Dividend Yield
- GAME N/A
- GNTA N/A
- EPS Growth
- GAME N/A
- GNTA N/A
- EPS
- GAME N/A
- GNTA N/A
- Revenue
- GAME $93,375,339.00
- GNTA N/A
- Revenue This Year
- GAME $2.32
- GNTA N/A
- Revenue Next Year
- GAME $26.42
- GNTA N/A
- P/E Ratio
- GAME N/A
- GNTA N/A
- Revenue Growth
- GAME 54.19
- GNTA N/A
- 52 Week Low
- GAME $0.50
- GNTA $2.33
- 52 Week High
- GAME $2.87
- GNTA $10.00
- Technical
- Relative Strength Index (RSI)
- GAME 44.13
- GNTA 42.95
- Support Level
- GAME $0.66
- GNTA $3.17
- Resistance Level
- GAME $0.75
- GNTA $10.00
- Average True Range (ATR)
- GAME 0.05
- GNTA 0.59
- MACD
- GAME 0.00
- GNTA 0.02
- Stochastic Oscillator
- GAME 23.79
- GNTA 0.91
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.